Comparative Pharmacology
Head-to-head clinical analysis: ARESTOCAINE HYDROCHLORIDE versus IONTOCAINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARESTOCAINE HYDROCHLORIDE versus IONTOCAINE.
ARESTOCAINE HYDROCHLORIDE vs IONTOCAINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Arestocaine hydrochloride is a local anesthetic of the amide type. It stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthesia.
Iontocaine (lidocaine 2% and epinephrine 0.01%) combines a sodium channel blocker (lidocaine) to inhibit nerve impulse propagation, producing local anesthesia, with epinephrine causing vasoconstriction to reduce systemic absorption and prolong effect.
2-5 mg/kg intramuscularly every 60-90 minutes, not to exceed 500 mg total dose in a 12-hour period.
IONTOCAINE is not a recognized drug. No standard dosing available.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5–2 hours in adults with normal hepatic and renal function; prolonged in hepatic impairment or congestive heart failure.
Terminal elimination half-life is 2.5-3.0 hours; prolonged in renal impairment (up to 6-8 hours).
Renal excretion of unchanged drug and metabolites; approximately 90% excreted in urine as parent compound and metabolites (60% as unchanged drug, 30% as metabolites), with less than 10% fecal elimination.
Primarily renal excretion of unchanged drug (70-80%) and glucuronide conjugate (15-20%); less than 10% fecal.
Category C
Category C
Local Anesthetic
Local Anesthetic